Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. (Q46427562)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

5

John Q Trojanowski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Benoit I Giasson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Roberto Hodara

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Shaohua Xu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Harry Ischiropoulos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Virginia M-Y Lee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

language of work or name

English

0 references

publication date

6 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

Journal of Biological Chemistry

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

280

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

21212-21219

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

Parkinson's disease. First of two parts

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Lewy bodies are ubiquitinated. A light and electron microscopic immunocytochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Characterization of a novel protein regulated during the critical period for song learning in the zebra finch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Identification of two distinct synucleins from human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Conformational properties of alpha-synuclein in its free and lipid-associated states

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Neuropathology of synuclein aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Alpha-synuclein and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Attenuation of dopamine transporter activity by alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Synthetic filaments assembled from C-terminally truncated alpha-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M412621200

21 January 2018

Identifiers

DOI

10.1074/JBC.M412621200

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15817478%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference